Suanfarma Suanfarma

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Spero Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Spero Reports Preliminary Findings from Phase 1 Clinical Trial of SPR206 and Plans to Advance Program with Alliance Partners Everest Medicines and the Department of Defense","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I"},{"orgOrder":0,"company":"Spero Therapeutics","sponsor":"Everest Medicines","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Everest Medicines Announces Amended Agreement with Spero Therapeutics","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I"},{"orgOrder":0,"company":"Spero Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$23.0 million","upfrontCash":"Undisclosed","newsHeadline":"Spero Therapeutics Awarded up to $23 Million by the National Institute of Allergy and Infectious Diseases for SPR206","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I"},{"orgOrder":0,"company":"Spero Therapeutics","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"$40.0 million","upfrontCash":"Undisclosed","newsHeadline":"Spero Therapeutics Announces $40 Million Equity Investment from Pfizer Inc. and Licensing Agreement for SPR206","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I"},{"orgOrder":0,"company":"Spero Therapeutics","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"$120.0 million","upfrontCash":"Undisclosed","newsHeadline":"Everest Medicines Announces that Spero Therapeutics Entered into Licensing Agreement with Pfizer Inc. for SPR206","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I"},{"orgOrder":0,"company":"Spero Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Spero Therapeutics Announces Clearance of IND for SPR206 to Treat MDR Gram-negative Bacterial Infections","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I"}]

    Find Clinical Drug Pipeline Developments & Deals for Spr 206

    Menu

    Spr 206

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Spero Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Spero Therapeutics Announces Clearance of IND for SPR206 to Treat MDR Gram-negative Bacterial Infections

              Details:

              SPR206 is a novel, intravenously (IV) administered next-generation polymyxin antibiotic for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) caused by MDR Gram-negative bacterial infections.

              Lead Product(s): SPR206

              Therapeutic Area: Infections and Infectious Diseases Product Name: SPR206

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable February 28, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Spero Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Everest Medicines Announces that Spero Therapeutics Entered into Licensing Agreement with Pfizer Inc. for SPR206

              Details:

              Spero has granted Pfizer the rights to develop, manufacture, and commercialize SPR206 in ex-U.S. and ex-Asia territories. SPR206 is a potentially best-in-class, novel polymyxin derivative that was designed to reduce the kidney toxicity in polymyxin B and colistin.

              Lead Product(s): SPR206

              Therapeutic Area: Infections and Infectious Diseases Product Name: SPR206

              Highest Development Status: Phase I Product Type: Large molecule

              Partner/Sponsor/Collaborator: Pfizer Inc

              Deal Size: $120.0 million Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement July 05, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Spero Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Spero Therapeutics Announces $40 Million Equity Investment from Pfizer Inc. and Licensing Agreement for SPR206

              Details:

              Spero grants Pfizer rights to develop, manufacture, and commercialize SPR206 in ex-U.S. and ex-Asia territories in exchange for potential development and commercial milestone payments and royalties.

              Lead Product(s): SPR206

              Therapeutic Area: Infections and Infectious Diseases Product Name: SPR206

              Highest Development Status: Phase I Product Type: Large molecule

              Partner/Sponsor/Collaborator: Pfizer Inc

              Deal Size: $40.0 million Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement June 30, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Spero Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Spero Therapeutics Awarded up to $23 Million by the National Institute of Allergy and Infectious Diseases for SPR206

              Details:

              The funding will support the further clinical development of SPR206, an IV-administered next-generation polymyxin product candidate derived from Spero’s potentiator platform that is being developed to treat serious MDR Gram-negative infections in the hospital setting.

              Lead Product(s): SPR206

              Therapeutic Area: Infections and Infectious Diseases Product Name: SPR206

              Highest Development Status: Phase I Product Type: Large molecule

              Partner/Sponsor/Collaborator: National Institutes of Health

              Deal Size: $23.0 million Upfront Cash: Undisclosed

              Deal Type: Funding May 17, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Spero Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Everest Medicines Announces Amended Agreement with Spero Therapeutics

              Details:

              Under an amended license agreement with Spero Therapeutics, the relevant patents for SPR206 will be assigned to Everest in Greater China, South Korea and certain Southeast Asian countries (the "Territory").

              Lead Product(s): SPR206

              Therapeutic Area: Infections and Infectious Diseases Product Name: SPR206

              Highest Development Status: Phase I Product Type: Large molecule

              Partner/Sponsor/Collaborator: Everest Medicines

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration January 18, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Spero Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Spero Reports Preliminary Findings from Phase 1 Clinical Trial of SPR206 and Plans to Advance Program with Alliance Partners Everest Medicines and the Department of Defense

              Details:

              Analysis of preliminary clinical trial in healthy volunteers suggests that SPR206 is well-tolerated at doses that are likely to be within a therapeutic range for target MDR Gram-negative bacterial infections.

              Lead Product(s): SPR206

              Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

              Highest Development Status: Phase I Product Type: Undisclosed

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 13, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Inke S.A: APIs manufacturing plant.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY